PDCD1 and cancer: In addition, CpG ODNs have been studied in combination with other drugs to treat cancers (Krieg, 2012; Scheiermann and Klinman, 2014), especially drugs of checkpoint inhibitors such as anti-programmed cell death 1 (PD-1) antibodies (Wang S. et al., 2016; Wang C. et al., 2016).